Actively Recruiting
TACTICAL Study Evaluating Early Tacrolimus Reduction After Allogeneic Hematopoietic Cell Transplant to Prevent GVHD
Led by Stanford University · Updated on 2026-08-17
50
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the early stopping of tacrolimus after allogeneic hematopoietic cell transplantation HCT to see if it is safe and practical. Tacrolimus is usually given after HCT to prevent graft-versus-host disease GVHD, but with new approaches like post-transplant cyclophosphamide PTCy, GVHD rates have decreased significantly. This study focuses on adults with certain blood cancers or disorders who undergo allogeneic HCT. Participants start tacrolimus on day 5 after transplant, initially given by standard dosing and then switched to oral tablets as tolerated. Tacrolimus levels are monitored multiple times per week to maintain target blood levels. From day 60, participants who qualify begin a gradual taper of tacrolimus, reducing their dose by about 20% each week, aiming to stop completely by day 88 unless safety concerns arise. During the study, participants have their tacrolimus levels checked frequently along with monitoring for safety and GVHD symptoms up to 180 days after transplant. Researchers will also track long-term outcomes such as chronic GVHD, infections, survival, relapse, and mortality for up to one year. The total study duration extends to about one year post-transplant with close medical follow-up.
CONDITIONS
Brief Title
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Research Team
K
Kelly Chyan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here